Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer

February 5th, 2019

Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced that it has appointed Brett Lauring, M.D., Ph.D. to the position of Chief Medical Officer.

“We are thrilled to have Brett join the Kallyope team as our CMO. Brett is uniquely qualified for this role having both early- and late-stage development experience and having worked in multiple therapeutic areas relevant to the gut-brain axis,” commented Nancy Thornberry, CEO of Kallyope. “Brett’s expertise will be critical in advancing our current portfolio of programs and in translating the novel, actionable biology we are identifying with our platform.”

Dr. Lauring joins Kallyope from Takeda Pharmaceuticals where he was Vice President, Translational Research and Early Clinical Development, responsible for managing the clinical development of compounds for gastrointestinal diseases through proof of concept. He previously spent 11 years at Merck working in both early and late clinical development roles in multiple therapeutic areas. In his most recent role at Merck, he was the Product Development Team Leader for the ertugliflozin program, advancing the lead molecule and two fixed-dose combinations through the Phase 3 program that led to approvals in the U.S., E.U., Canada and other markets. Prior to that, Dr. Lauring was responsible for early clinical development for the diabetes therapeutic area and led numerous programs in the neuroscience and cardiovascular therapeutic areas.

Before joining Merck, Dr. Lauring was assistant professor at Columbia University’s College of Physicians & Surgeons where his laboratory elucidated novel mechanisms underlying axonal degenerative diseases. He completed his residency in anatomic pathology at New York Presbyterian Hospital/Cornell. He received his M.D. and Ph.D. degrees from NYU School of Medicine and a B.A. in philosophy from Yale.

“I am excited to join Kallyope as a number of promising drug discovery programs are emerging from its platform,” said Dr. Lauring. “Kallyope’s leadership in the gut-brain axis field will enable it to advance multiple novel programs forward in diseases of high unmet need.”

About Kallyope Inc.

Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company’s cross-disciplinary team integrates cutting-edge technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. The company’s founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D., and Nobel laureate Richard Axel, M.D. For more information visit www.kallyope.com.

Contact

Morgan Warners
(202) 337-0808
mwarners@gpg.com


Back to News